Lonza to Sell CHI Business to Lone Star Funds for ~$3B

Shots: Lonza has agreed to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3B (~$3B), receiving CHF 1.7B (~$2.2B) upfront while retaining a 40% stake with preferential participation in future exit proceeds Lonza is expecting total undiscounted proceeds of ≥CHF 3B (~$4B) from CHI via…

ByRidhi RastogiMarch 9, 2026

NEWS

GAIA and Daiichi Sankyo Europe Partner to Launch Lipodia for Hypercholesterolemia in Europe

Shots: GAIA has entered into an exclusive strategic partnership with Daiichi Sankyo Europe to commercialize Lipodia, a digital therapeutic designed to support adults living with hypercholesterolemia, upon regulatory approval As per the deal, Daiichi Sankyo Europe will obtain exclusive rights to lipodia, initially covering Germany, with provisions to expand the partnership across major EU markets…

ByRidhi RastogiMarch 6, 2026

NEWS

Tenaya Therapeutics and Alnylam Pharmaceuticals Partner to Discover Novel Genetic Targets for CV Therapies in ~$1.13B Deal

Shots: Tenaya has entered into a research collaboration with Alnylam to identify novel human genetic targets that could enable the development of disease-modifying therapies for cardiovascular (CV) diseases Under the collaboration, Tenaya will validate up to 15 gene targets, while Alnylam will lead all the development & commercialization of therapies arising from these validated targets…

ByRidhi RastogiMarch 6, 2026

NEWS

Teva Lands $400M Blackstone Life Sciences Deal to Support Duvakitug Development

Shots: Teva & Blackstone Life Sciences have entered a four-year strategic funding agreement to support the continued clinical development of duvakitug As per the deal, Blackstone will provide $400M to Teva over four years to fund duvakitug development, while Blackstone will receive potential milestone payment subject to FDA approval, & additional commercial milestones, as well…

ByRidhi RastogiMarch 5, 2026

NEWS

Sino Biopharmaceutical and Sanofi Partner to Advance Rovadicitinib in a ~$1.53B Deal

Shots: Sino Biopharm via its subsidiary Chia Tai Tianqing has entered into an exclusive license agreement with a fully owned subsidiary of Sanofi for rovadicitinib As per the deal, Sanofi will obtain exclusive global license to develop, manufacture & commercialize rovadicitinib in exchange for $135M upfront & ~$1.395B in development, regulatory & sales milestones, as…

ByRidhi RastogiMarch 5, 2026

NEWS

Antengene and UCB Strike ~$1.18B Deal to Advance ATG-201 for B-Cell–Related Autoimmune Diseases

Shots: Antengene has granted UCB a global exclusive license to develop, manufacture, & commercialize ATG-201 for B-cell–related autoimmune diseases, plus access to Antengene’s associated manufacturing tech supporting the therapy As per the deal, Antengene will receive $80M in upfront & near-term milestones & ~$1.1B in development & commercial milestones, as well as net sales-based tiered…

ByRidhi RastogiMarch 5, 2026

NEWS

Moderna settles LNP Patent Dispute with Genevant Sciences and Arbutus Biopharma for ~$2.25B

Shots: Genevant & Arbutus reached a global settlement with Moderna to resolve all US & international disputes over the alleged unauthorized use of their LNP delivery technology in the COVID-19 vaccines, incl. Spikevax As part of the settlement, Moderna will pay $950M upfront to Genevant & Arbutus in Jul 2026 & ~$1.3B more pending…

ByRidhi RastogiMarch 5, 2026

NEWS

Zymeworks Raises $250M from Royalty Pharma Backed by Ziihera Royalties

Shots: Zymeworks secured $250M from Royalty Pharma via a non-recourse royalty-backed note, repayable from 30% of worldwide tiered royalties on Ziihera owed by Jazz Pharmaceuticals and BeOne Medicines Royalty will receive payments until it achieves 1.65x of the note by Dec 31, 2033, or 1.925x thereafter; Zymeworks retains 70% of royalties during repayment, with full…

ByRidhi RastogiMarch 2, 2026

NEWS

Boehringer Ingelheim Inks $500M+ Deal with Sitryx Therapeutics for Novel Oral Immune Disease Therapies

Shots: Sitryx Therapeutics has granted BI an exclusive license to a preclinical, small molecule program, offering a disease-modifying treatment approach across multiple autoimmune & inflammatory disease indications As per the deal, BI will receive an exclusive global license to the multiple assets & related IP to the small molecule inhibitor program, plus it will assume…

ByRidhi RastogiFebruary 27, 2026

NEWS

Novo Nordisk and Vivtex Partner in ~2.1B Metabolic Deal to Develop Oral Therapies

Shots: Novo Nordisk has partnered with Vivtex to develop next-generation oral biologics for obesity, diabetes, & related comorbidities, leveraging Vivtex’s GI screening & formulation platform Vivtex will license select oral drug-delivery techs to Novo, which will lead global development, regulatory, manufacturing & commercialization, while Vivtex will receive an upfront, research funding, & milestone payments totalling…

ByRidhi RastogiFebruary 26, 2026

Lonza to Sell CHI Business to Lone Star Funds for ~$3B

GAIA and Daiichi Sankyo Europe Partner to Launch Lipodia for Hypercholesterolemia in Europe

Tenaya Therapeutics and Alnylam Pharmaceuticals Partner to Discover Novel Genetic Targets for CV Therapies in ~$1.13B Deal

Teva Lands $400M Blackstone Life Sciences Deal to Support Duvakitug Development

Sino Biopharmaceutical and Sanofi Partner to Advance Rovadicitinib in a ~$1.53B Deal

Antengene and UCB Strike ~$1.18B Deal to Advance ATG-201 for B-Cell–Related Autoimmune Diseases

Moderna settles LNP Patent Dispute with Genevant Sciences and Arbutus Biopharma for ~$2.25B

Zymeworks Raises $250M from Royalty Pharma Backed by Ziihera Royalties

Boehringer Ingelheim Inks $500M+ Deal with Sitryx Therapeutics for Novel Oral Immune Disease Therapies

Novo Nordisk and Vivtex Partner in ~2.1B Metabolic Deal to Develop Oral Therapies

Contact US

FOLLOW US